Gompertz law based biological age (GOLD BioAge): a simple and practical measurement of biological aging to capture morbidity and mortality risks
Preprint
Abstract
Biological age reflects actual aging and overall health, but current aging clocks are often complex and difficult to interpret, limiting their clinical application. In this study, we introduced a Gompertz law-based biological age (GOLD BioAge) model that simplified aging assessment. We estimated GOLD BioAge using clinical biomarkers and found significant associations of the difference from chronological age (BioAgeDiff) with risks of morbidity and mortality in NHANES. Moreover, we developed GOLD ProtAge and MetAge using proteomics and metabolomics data, which outperformed the clinical-only model in predicting mortality and chronic disease risks in UK Biobank. Benchmark analysis illustrated that our models exceeded common aging clocks in predicting mortality across diverse age groups in both NHANES and UK Biobank. The results demonstrated that the GOLD BioAge algorithm effectively applied to both clinical and omics data, showing excellent performance in predicting age-related outcomes. Additionally, we created a simplified version called the Light BioAge, which used three biomarkers for aging assessment. The Light model reliably captured mortality risks in three validation cohorts (CHARLS, RuLAS, CLHLS). It significantly predicted the onset of frailty, stratified frail individuals, and collectively identified individuals at high risk of mortality. In summary, the algorithm of GOLD BioAge could provide a valuable framework for aging assessment in public health and clinical practice. Highlights: The algorithm of Gompertz law based biological age (GOLD BioAge) was proposed to construct biological aging clocks with convenient and interpretable calculations, which had better performance in predicting mortality risks. Our approach was applicable to proteomics and metabolomics, yielding ProtAge and MetAge with great clinical prospect to improve accuracy of aging assessment and prevent age-related diseases. The Light BioAge, a simplified version, was developed using age and three biomarkers, and it independently predicted mortality in three cohorts. The Light BioAgeDiff significantly predicted the onset of frailty, stratified frail individuals, and collectively identified individuals at high risk of mortality.Keywords
All Related Versions
- Published version: Advanced Science, 12 (32), e01765.
This publication has 72 references indexed in Scilit:
- Tumor necrosis factor superfamily signaling: life and death in cancerCancer and Metastasis Reviews, 2024
- A Novel Metabolomic Aging Clock Predicting Health Outcomes and Its Genetic and Modifiable FactorsAdvanced Science, 2024
- Plasma LTBP2 as a potential biomarker in differential diagnosis of connective tissue disease-associated interstitial lung disease and idiopathic pulmonary fibrosis: a pilot studyClinical and Experimental Medicine, 2023
- Chinese Longitudinal Healthy Longevity Survey (CLHLS)2021
- Renal renin secretion as regulator of body fluid homeostasisPflügers Archiv - European Journal of Physiology, 2012
- Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome?Acta Diabetologica, 2009
- A nonrandom association between gastrointestinal stromal tumors and myeloid leukemiaCancer, 2007
- Serum insulin‐like growth factor‐I, insulin‐like growth factor binding protein‐3, and the risk of pancreatic cancer deathInternational Journal of Cancer, 2004
- Skeletal muscle satellite cell proliferation in response to members of the fibroblast growth factor family and hepatocyte growth factorJournal of Cellular Physiology, 1999
- Effect of Epidermal Growth Factor, Hepatocyte Growth Factor, and Keratinocyte Growth Factor, on Proliferation, Motility and Differentiation of Human Corneal Epithelial CellsExperimental Eye Research, 1994